136 related articles for article (PubMed ID: 32656077)
1. A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an
Chen D; Li XL; Wu B; Zheng XB; Wang WX; Chen HF; Dong YY; Xu CW; Fang MY
Front Oncol; 2020; 10():867. PubMed ID: 32656077
[No Abstract] [Full Text] [Related]
2. Lung Adenocarcinoma Patient Harboring
Zhao L; Wang Z; Du H; Chen S; Wang P
Front Oncol; 2021; 11():605853. PubMed ID: 33898306
[TBL] [Abstract][Full Text] [Related]
3. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
[TBL] [Abstract][Full Text] [Related]
4. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
Long X; Qin T; Lin J
Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis and clinical outcome of a lung cancer patient with
Yang D; Han X; Li D; Cui S; Liu S; Wu X; Dai Z
Am J Transl Res; 2020; 12(10):6689-6693. PubMed ID: 33194065
[TBL] [Abstract][Full Text] [Related]
6. The landscape of kinase domain duplication in Chinese lung cancer patients.
Wu D; Xie Y; Jin C; Qiu J; Hou T; Du H; Chen S; Xiang J; Shi X; Liu J
Ann Transl Med; 2020 Dec; 8(24):1642. PubMed ID: 33490154
[TBL] [Abstract][Full Text] [Related]
7. Lung Adenocarcinoma Harboring
Li J; Yan J; Cao R; Du G; Zhao G
Front Oncol; 2020; 10():575739. PubMed ID: 33392076
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
Wang J; Li X; Xue X; Ou Q; Wu X; Liang Y; Wang X; You M; Shao YW; Zhang Z; Zhang S
Int J Cancer; 2019 Jun; 144(11):2677-2682. PubMed ID: 30255937
[TBL] [Abstract][Full Text] [Related]
9. A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report.
Wang X; Huang L; Cai J; Liu A
Onco Targets Ther; 2021; 14():3739-3744. PubMed ID: 34163176
[TBL] [Abstract][Full Text] [Related]
10. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
[TBL] [Abstract][Full Text] [Related]
11. Response to Afatinib in a Patient with NSCLC Harboring Novel
Lin L; Wu X; Yan S; Zhu Y; Yan Z; Lv D; Ge H
Onco Targets Ther; 2020; 13():9753-9757. PubMed ID: 33061454
[TBL] [Abstract][Full Text] [Related]
12. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors.
Kondo T; Kikuchi O; Yamamoto Y; Sunami T; Wang Y; Fukuyama K; Saito T; Nakahara H; Minamiguchi S; Kanai M; Sueyoshi A; Muto M
Oncologist; 2024 May; ():. PubMed ID: 38821532
[TBL] [Abstract][Full Text] [Related]
15. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
18. Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report.
Ma C; Wang S; Mu N; Li J; Liu M; Li L; Jiang R
Front Oncol; 2020; 10():1635. PubMed ID: 33014823
[No Abstract] [Full Text] [Related]
19. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
20. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]